Research Analysts Set Expectations for CareDx Q2 Earnings

CareDx, Inc (NASDAQ:CDNA) – Research analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of CareDx in a research note issued on Monday, May 5th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.09) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright currently has a “Neutral” rating and a $25.00 target price on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.26 EPS.

A number of other research firms have also commented on CDNA. The Goldman Sachs Group cut their price target on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and cut their target price for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Stephens reiterated an “overweight” rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Finally, StockNews.com lowered shares of CareDx from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

CareDx Trading Up 0.2 %

CDNA opened at $15.42 on Thursday. The company has a 50 day moving average of $17.87 and a 200 day moving average of $21.16. CareDx has a 12 month low of $12.53 and a 12 month high of $34.84. The company has a market cap of $858.60 million, a PE ratio of -5.71 and a beta of 2.27.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. During the same quarter last year, the business earned ($0.03) earnings per share. The company’s quarterly revenue was up 17.6% on a year-over-year basis.

Insider Transactions at CareDx

In related news, Director Christine Cournoyer sold 16,700 shares of the company’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total value of $235,971.00. Following the completion of the transaction, the director now directly owns 37,045 shares in the company, valued at approximately $523,445.85. The trade was a 31.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter Maag sold 13,281 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now owns 316,743 shares in the company, valued at $5,457,481.89. The trade was a 4.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,246 shares of company stock valued at $469,498. 4.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CDNA. Principal Financial Group Inc. lifted its holdings in shares of CareDx by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 19,624 shares of the company’s stock worth $348,000 after acquiring an additional 640 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock worth $344,000 after purchasing an additional 950 shares during the period. Hsbc Holdings PLC raised its position in CareDx by 6.9% in the 4th quarter. Hsbc Holdings PLC now owns 17,131 shares of the company’s stock worth $365,000 after purchasing an additional 1,109 shares during the period. Legal & General Group Plc lifted its stake in CareDx by 1.3% in the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company’s stock worth $1,922,000 after purchasing an additional 1,118 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its position in CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock valued at $27,000 after buying an additional 1,126 shares during the period.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.